PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment
Download 843.4 KBPeer reviewed scientific article
English
SCIENSANO
Authors
J. Thouvenin1,2 [2]; C. Van Marcke3 [3]; L. Decoster4 [4]; Gordana Raicevic [5]; K. Punie [6]; M. Vandenbulcke5 [7]; R. Salgado [8]; Els Van Valckenborgh [9]; B. Maes [10]; S. Joris [11]; D. Vander Steichel [12]; K. Vranken [13]; S. Jacobs [14]; F. Dedeurwaerdere12 [15]; G. Martens [16]; F. H. Devos [17]; F. P. Duhoux [18]; M. Rasschaert [19]; P. Pauwels [20]; K. Geboes [21]; J. Collignon20 [22]; S. Tejpar [23]; J.-L. Canon21 [24]; M. Peeters [25]; A. Rutten [26]; T. Van de Mooter23 [27]; J. Vermeij [28]; D. Schrijvers [29]; W. Demey [30]; W. Lybaert [31]; J. Van Huysse27 [32]; J. Mebis [33]; A. Awada [34]; K. B. M. Claes [35]; Aline Hébrant [36]; J. Van der Meulen [37]; B. Delafontaine30 [38]; I. Vanden Bempt [39]; J Maetens [40]; Maïté de Hemptinne [41]; S. Rottey [42]; P. Aftimos [43]; J. De Grève4 [44]Keywords
Abstract:
PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinicogenomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 p…